HbA1c with Estimated Average Glucose (eAG) Test
The HbA1c with eAG test measures glycated haemoglobin, reflecting average glycaemia over the preceding two to three months, and reports it both as a percentage and as an estimated average glucose in familiar glucose units. It is the cornerstone test for diagnosing and monitoring diabetes and identifying prediabetes, does not require fasting, and is unaffected by short-term fluctuations, though…
2
Biomarkers
Blood (whole blood)
Sample
1–2 business days
Turnaround
No
Fasting
What is the HbA1c (with eAG) test?
The HbA1c with eAG Test measures glycated haemoglobin, the proportion of haemoglobin modified by glucose, and reports the result both as a percentage and as an estimated average glucose in familiar glucose units. Because glycation accumulates over the red cell's lifespan, HbA1c reflects average glycaemia over the preceding two to three months, providing a stable, fasting-independent measure of chronic glucose control. In the diagnostic landscape, HbA1c is the cornerstone test for diabetes, used to diagnose diabetes and prediabetes and to monitor glycaemic control against individualised targets. Its advantages over fasting or random glucose are that it does not require fasting, is not affected by short-term fluctuations, and integrates control over months. The eAG component translates the percentage into the glucose units patients see on home meters, aiding communication without adding independent information. Practitioners order it to establish or exclude diabetes, to track treatment response, and to assess complication risk, interpreting it with awareness that conditions altering red cell turnover — haemoglobinopathies, anaemia, recent transfusion — can make it unreliable.
What does the HbA1c (with eAG) test measure?
Haemoglobin A1c is formed by the non-enzymatic glycation of haemoglobin in proportion to ambient glucose over the lifespan of the red cell. Because erythrocytes survive roughly 120 days, HbA1c reflects average glycaemia over the preceding two to three months, weighted toward the most recent weeks. It is a stable, standardised measure that does not require fasting and is unaffected by short-term glucose fluctuations.
HbA1c is the cornerstone test for diagnosing and monitoring diabetes and for identifying prediabetes, providing an integrated measure of chronic glycaemic control. It is used to establish the diagnosis, to guide and monitor treatment against individualised targets, and to assess risk of diabetes-related complications. Its reliability depends on normal red cell turnover, and it can mislead in haemoglobinopathies, anaemia, and altered erythrocyte lifespan.
Estimated average glucose is a calculated value derived directly from HbA1c using the validated ADAG relationship, expressing the HbA1c result in the same glucose units patients see on home meters. It is not a separately measured analyte but a translation of HbA1c intended to make chronic glycaemic control more intuitive.
eAG helps practitioners and patients relate the HbA1c percentage to familiar day-to-day glucose readings, supporting communication and self-management. Because it is derived from HbA1c, it carries the same strengths and limitations and adds no independent information beyond presenting the result in glucose units.
Why is the HbA1c (with eAG) test ordered?
- Diagnosis of diabetes and identification of prediabetes in at-risk or symptomatic patients
- Routine monitoring of glycaemic control in established diabetes against individualised targets
- Screening for diabetes in patients with risk factors such as obesity, family history, or metabolic syndrome
- Assessment of glycaemic control where fasting is impractical, given HbA1c does not require fasting
- Evaluation of treatment response after changes to diabetes therapy or lifestyle intervention
- Assessment of complication risk in diabetes, where chronic control predicts microvascular outcomes
- Monitoring in pregnancy-related or gestational diabetes contexts where appropriate, interpreted with the relevant caveats
- Communication of chronic glucose control to patients via the estimated average glucose value
Sample collection and turnaround
Sample type
Blood (whole blood)
Fasting required
No
Collection method
Venipuncture at patient service centre
Turnaround
1–2 business days
Collection notes
No fasting required. Collected into an EDTA whole-blood tube per protocol. Document anaemia, haemoglobinopathy, recent transfusion, pregnancy, and CKD, as these affect reliability. # REVIEWER FLAG: Confirm tube type and assay with LabCorp.
Specimen requirements
EDTA whole blood per LabCorp protocol; adequate fill and mixing required.
What can affect HbA1c (with eAG) results?
Variant haemoglobins (e.g. HbS, HbC, HbE) can interfere with certain HbA1c assays, producing falsely high or low results depending on the method. Assay choice matters in affected populations. # REVIEWER FLAG: Confirm LabCorp assay's variant interference profile.
Haemolysis, recent blood loss, and conditions with rapid red cell turnover reduce the time available for glycation, falsely lowering HbA1c relative to true glycaemia.
Iron, B12, or folate deficiency anaemia and splenectomy prolong red cell survival, increasing glycation time and falsely raising HbA1c. Iron deficiency in particular commonly raises HbA1c.
Transfused red cells introduce a mixed population with different glycation histories, distorting HbA1c until equilibration.
Altered red cell turnover, carbamylation, and erythropoietin therapy in CKD can shift HbA1c independent of glycaemia, complicating interpretation.
Increased red cell turnover and physiological changes in pregnancy lower HbA1c, so it is less reliable for glycaemic assessment in pregnancy and is interpreted with caution.
What do HbA1c (with eAG) results mean?
Elevated
An HbA1c of 6.5% (48 mmol/mol) or above is consistent with diabetes, and 5.7–6.4% (39–46 mmol/mol) indicates prediabetes, each ideally confirmed per diagnostic protocol. In established diabetes, a rising or above-target HbA1c indicates inadequate control and prompts treatment intensification, interpreted against the individualised target.
Normal
An HbA1c below 5.7% (39 mmol/mol) is normal and argues against diabetes at the time of testing. A normal value does not exclude conditions that mask true glycaemia through altered red cell turnover, so discordance with glucose readings warrants further assessment.
Reduced
A low HbA1c usually reflects good glycaemic control or, in non-diabetic individuals, normal glucose metabolism. A spuriously low value can arise from conditions shortening red cell lifespan, which should be considered if the result is discordant with other glucose measures.
Note: HbA1c reliability depends on normal red cell turnover; haemoglobinopathies, anaemia, recent transfusion, pregnancy, and CKD can all make it misleading, and discordance with glucose measurements should prompt review. The eAG is a translation of HbA1c, not an independent measurement, and shares its limitations. Diagnostic thresholds should be applied per the relevant guideline, with confirmation as protocol requires.
Frequently asked questions
It measures glycated haemoglobin, the proportion of haemoglobin modified by glucose, which reflects average glycaemia over the preceding two to three months. It is the cornerstone test for diagnosing and monitoring diabetes.
How to access the HbA1c (with eAG) test
The HbA1c (with eAG) reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: June 3, 2026
Last reviewed: June 3, 2026
- American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes. Diabetes Care. (2020)
- Nathan DM, et al. Translating the A1C assay into estimated average glucose values (ADAG study). Diabetes Care. (2008)
- Little RR, et al. Standardization of HbA1c and the National Glycohemoglobin Standardization Program. Clin Chem. (2011)
- Radin MS. Pitfalls in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med. (2014)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.